Xeris In Recorlev-Fuelled Growth: Why I Choose To Buy

Xeris Biopharma (XERS) reported a strong Q2 2025, achieving record revenue of $71.5 million (+49% YoY) and its first positive adjusted EBITDA of $12.5 million, largely driven by Recorlev's 136% revenue surge, positioning the company for Q3 breakeven. While Recorlev and the promising Phase 3-ready pipeline asset XP-8121 offer significant growth potential, Xeris faces a substantial $218.6 million long-term debt, which could create funding challenges for XP-8121's trials by late 2026. The stock's elevated valuation (30.96x forward EV/EBITDA) reflects market optimism but also implies execution risk given its future capital requirements.

Analysis

Xeris Biopharma Holdings (XERS) demonstrated significant operational momentum in its Q2 2025 results, achieving record quarterly revenue of $71.5 million, a 49% year-over-year increase, and its first-ever positive adjusted EBITDA of $12.5 million. This performance is primarily propelled by its Cushing’s syndrome therapy, Recorlev, which saw revenue surge 136% YoY and now constitutes 44% of total revenue. The company's portfolio is in different lifecycle stages: Recorlev is in a high-growth phase, Gvoke provides stable, mature growth with a 17.5% YoY increase, and Keveyis is in late maturity with declining revenue contribution. This strong top-line growth, coupled with stable SG&A expenses, positions the company to potentially reach operational breakeven in Q3 2025. However, this near-term strength is counterbalanced by significant medium-term risks. The company carries a substantial long-term debt of $218.6 million against a cash position of $59.3 million, creating a potential funding gap for the capital-intensive Phase 3 trials of its lead pipeline asset, XP-8121, scheduled to begin in 2026. Furthermore, the stock's premium valuation, indicated by a forward EV/EBITDA multiple of 30.96, reflects high market expectations for both sustained Recorlev adoption and a successful pipeline, exposing investors to execution risk.

Key Decisions for Investors

• Investors should weigh the company's strong near-term operational momentum, driven by Recorlev's rapid adoption and a clear path to profitability, against its high valuation.
• Monitor the company's balance sheet and cash burn closely, as the $218.6 million long-term debt presents a material funding risk for the pivotal XP-8121 Phase 3 trial, which may necessitate external capital by late 2026.
• Recognize that the premium valuation prices in significant growth and pipeline success, making the stock vulnerable to pullbacks if Recorlev's growth decelerates or if there are delays in the XP-8121 development timeline.
• Long-term success is heavily dependent on the XP-8121 pipeline asset, so any updates on its 2026 trial initiation and subsequent progress are critical catalysts to watch.